Andrew A Raubitschek
Overview
Explore the profile of Andrew A Raubitschek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mortimer J, Bading J, Park J, Frankel P, Carroll M, Tran T, et al.
J Nucl Med
. 2017 Jun;
59(1):38-43.
PMID: 28637802
The goal of this study was to characterize the relationship between tumor uptake of Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor...
2.
Sta Maria N, Barnes S, Weist M, Colcher D, Raubitschek A, Jacobs R
PLoS One
. 2015 Nov;
10(11):e0142767.
PMID: 26556731
Natural killer (NK) cells play a vital antitumor role as part of the innate immune system. Efficacy of adoptive transfer of NK cells depends on their ability to recognize and...
3.
Mortimer J, Bading J, Colcher D, Conti P, Frankel P, Carroll M, et al.
J Nucl Med
. 2013 Dec;
55(1):23-9.
PMID: 24337604
Unlabelled: Women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are candidates for treatment with the anti-HER2 antibody trastuzumab. Assessment of HER2 status in recurrent disease is usually...
4.
Ng T, Wert D, Sohi H, Procissi D, Colcher D, Raubitschek A, et al.
Clin Cancer Res
. 2013 Mar;
19(9):2518-27.
PMID: 23532891
Purpose: Targeted nanotherapies are being developed to improve tumor drug delivery and enhance therapeutic response. Techniques that can predict response will facilitate clinical translation and may help define optimal treatment...
5.
Ng T, Bading J, Park R, Sohi H, Procissi D, Colcher D, et al.
J Nucl Med
. 2012 Jun;
53(7):1102-9.
PMID: 22661534
Unlabelled: Noninvasive methods are needed to explore the heterogeneous tumor microenvironment and its modulation by therapy. Hybrid PET/MRI systems are being developed for small-animal and clinical use. The advantage of...
6.
Gagnon P, Cheung C, Lepin E, Wu A, Sherman M, Raubitschek A, et al.
Bioprocess Int
. 2011 Oct;
8(2):26-35.
PMID: 21984873
This case study describes early phase purification process development for a recombinant anticancer minibody produced in mammalian cell culture. The minibody did not bind to protein A. Cation-exchange, anion-exchange, hydrophobic-interaction,...
7.
Li L, Crow D, Turatti F, Bading J, Anderson A, Poku E, et al.
Bioconjug Chem
. 2011 Mar;
22(4):709-16.
PMID: 21395337
Optimal PET imaging of tumors with radiolabeled engineered antibodies requires, among other parameters, matching blood clearance and tumor uptake with the half-life of the engineered antibody. Although diabodies have favorable...
8.
James S, Greenberg P, Jensen M, Lin Y, Wang J, Budde L, et al.
J Immunol
. 2010 Mar;
184(8):4284-94.
PMID: 20220093
We investigated relationships among chimeric TCR (cTCR) expression density, target Ag density, and cTCR triggering to predict lysis of target cells by cTCR(+) CD8(+) T human cells as a function...
9.
Olafsen T, Sirk S, Betting D, Kenanova V, Bauer K, Ladno W, et al.
Protein Eng Des Sel
. 2010 Jan;
23(4):243-9.
PMID: 20053640
Rapid clearing engineered antibody fragments for immunoPET promise high sensitivity at early time points. Here, tumor targeting of anti-CD20 diabodies (scFv dimers) for detection of low-grade B-cell lymphomas were evaluated....
10.
Olafsen T, Betting D, Kenanova V, Salazar F, Clarke P, Said J, et al.
J Nucl Med
. 2009 Aug;
50(9):1500-8.
PMID: 19690034
Unlabelled: The CD20 cell surface antigen is expressed at high levels by over 90% of B-cell non-Hodgkin lymphomas (NHL) and is the target of the anti-CD20 monoclonal antibody rituximab. To...